Skip to Content

Telotristat etiprate Approval Status

  • FDA approved: No
  • Generic name: telotristat etiprate
  • Company: Lexicon Pharmaceuticals, Inc.
  • Treatment for: Carcinoid Syndrome

Telotristat etiprate is an oral tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome.

Development Status and FDA Approval Process for telotristat etiprate

DateArticle
Sep 14, 2016FDA Extends PDUFA Date for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
May 31, 2016Lexicon Announces FDA Priority Review of NDA for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
Mar 30, 2016Lexicon Submits New Drug Application to FDA for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
Mar  9, 2015Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of Telotristat Etiprate
Oct 12, 2012Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
Aug  9, 2011Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide